One detail we are very excited about: the potential for PCIPs to selectively target tumors with acquired resistance to conventional PARP inhibitors. while KO of PARP1 is a major mechanism of resistance to PARPi, PARP1 knockout cells are actually more sensitive to PCIP-1. (3/3)